

**Vietnam Pneumococcal Vaccine Market Assessment, By Type of Vaccine [Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Recombinant Vaccines], By Vaccine Property [Adjuvanted, Non-adjuvanted], By Route of Administration [Intramuscular, Subcutaneous, Intradermal, Others], By Age Group [Infants, Children, Adults], By End-user [Hospitals, Specialty Clinics, Homecare, Others], By Distribution Channel [Hospital, Retail Pharmacy, Online Pharmacy, Non-Governmental Organizations], By Region, By Opportunities and Forecast, 2017-2031F**

Market Report | 2024-04-19 | 129 pages | Market Xcel - Markets and Data

**AVAILABLE LICENSES:**

- Single User License \$3300.00
- Multi-User/Corporate Licence \$4500.00
- Custom Research License \$7000.00

**Report description:**

Vietnam pneumococcal vaccine market is projected to witness a CAGR of 8.23% during the forecast period 2024-2031, growing from USD 100.01 million in 2023 to USD 188.29 million in 2031. The Vietnam pneumococcal vaccine market is experiencing robust growth driven by multiple factors, such as an increased awareness of vaccination programs, a rise in pneumococcal disease incidences, and a growing elderly population that is particularly susceptible to severe infections. Additionally, governments and international health organizations are playing an active role in enhancing immunization programs and implementing initiatives to alleviate the burden of pneumococcal diseases, further bolstering the expansion of the Vietnam pneumococcal vaccine market. The Vietnam pneumococcal vaccine market is significantly impacted by the rising incidence of pneumonia. Pneumonia primarily strikes susceptible populations, including children, the elderly, and those with weakened immune systems. There are now more

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

awareness-raising campaigns because of the rise in instances. Moreover, due to the efforts of pharmaceutical companies and research organizations to provide comprehensive treatments against pneumococcal diseases, the Vietnam pneumococcal vaccine market has seen outstanding progress and creativity. Pneumococcal vaccination availability and accessibility have significantly improved because of technological developments and increased spending on healthcare infrastructure.

Additionally, government programs and alliances with global health organizations have had a big impact on the growth of the Vietnam pneumococcal vaccine market. As proactive immunization programs and tactical partnerships have gained traction, vaccine coverage has grown, and public awareness of pneumococcal illnesses has grown.

#### High Prevalence of Pneumonia

Vietnam ranks among the top 15 countries with the highest prevalence of child pneumonia. This respiratory condition is a major cause of hospital admissions in pediatric hospitals in Vietnam. Various risk factors contribute to severe pneumonia among children under the age of 5 in Vietnam, including malnutrition, inadequate breastfeeding practices, insufficient vaccinations, low birth weight, indoor pollution, and overcrowded living conditions. The impact of pneumonia on young children in Vietnam is well-documented; however, little is known about the prevalence of severe pneumonia and its risk factors in this age group. Therefore, the primary driver of the Vietnam pneumococcal vaccine market's expansion is the country's high rate of pneumonia cases.

#### Technological Advancements are Driving the Market

Technological advancements are responsible for the upsurge in the growth of the Vietnam pneumococcal vaccine market. Pneumococcal vaccinations were first developed utilizing whole-cell-based techniques. These entailed immunizing patients with heat-killed serotype 1 bacteria, which had afflicted South African miners. Nonetheless, studies by MacLeod et al. demonstrated that the sickness was prevented by immunization with capsular polysaccharides. Consequently, pure capsular polysaccharides were used in vaccine formulations. It is noteworthy that every pneumococcal serotype has biochemical and antigenic differences. It would be unfeasible to attain universal capsule-based immunization coverage against the hundreds of serotypes that are now in use. Rather, pure capsular polysaccharides from a small number of serotypes that cause human illness most frequently make up the pneumococcal vaccinations that are currently in use. Presently, most licensing agencies approve two types of vaccines containing capsular polysaccharides: one composed of 23 purified capsules (PPSV) and the other composed of 7, 10, or 13 purified capsules conjugated to a protein carrier (PCV). These vaccine formulations are significantly responsible for the growth of the Vietnam pneumococcal vaccine market.

#### The Demand for Pneumococcal Conjugate Vaccine is on the Rise

The extraordinary impact of the pneumococcal conjugate vaccination (PCV) is substantially responsible for the expansion of the Vietnam pneumococcal vaccine market. PCV is specially designed to boost the immune system's reaction to certain polysaccharides found on the bacteria's surface. These polysaccharides bind to carrier proteins through a process known as conjugation, which greatly improves the immune system's capacity to recognize and successfully fight the infection. Because of its novel architecture, PCV not only boosts immunity but also offers broader protection against a larger variety of pneumococcal serotypes. This transformative vaccine has emerged as a vital tool in reducing the burden of pneumococcal-related diseases and has played a pivotal role in safeguarding public health on a global scale. In 2021, a trial of pneumococcal vaccine schedules for PCV10 and PCV 13 was conducted in Ho Chi Minh City, Vietnam. The trial was sponsored by Murdoch Children's Research Institute, an Australian pediatric medical research institute located in Melbourne, Victoria.

#### Intramuscular Vaccines are in Great Demand

High demand for intramuscular vaccines is driving the Vietnam pneumococcal vaccine market. Intramuscular vaccinations are preferred due to their ability to elicit a strong immune response. Strong and long-lasting immune system activation is made possible by the muscle tissue's abundant blood supply and greater concentration of antigen-presenting cells. This ultimately results in a notable upsurge in the generation of protective antibodies and cultivates an improved immune memory, both of which are essential for sustained protection against pneumococcal infections. On the other hand, intradermal delivery entails injecting the vaccine into the skin's underlying layer. Although there is evidence to support the usefulness of this method in eliciting a robust and long-lasting immune response for pneumococcal immunization, it is not as well-supported as other vaccines.

#### Future Market Scenario (2024-2031F)

-Vietnam pneumococcal vaccine market will also be influenced by the active role of healthcare organizations in enhancing

immunization programs.

-□The increasing awareness regarding pneumonia disease will propel the growth of the Vietnam pneumococcal vaccine market in the future.

-□Several products by different companies are in the pipeline which are likely to be launched in coming years. Thus, the availability of new vaccine formulations will drive the growth of the Vietnam pneumococcal vaccine market.

-□The shift in population demographics toward the geriatric population will cause an increase in the overall number of people with diseases, such as Pneumonia, thereby propelling the market expansion.

#### Key Players Landscape and Outlook

Over the years, the Vietnam pneumococcal vaccine market has undergone significant changes, spurred by the urgent mission to combat pneumococcal diseases and safeguard public health. Recognizing the gravity of this health challenge, a multitude of pharmaceutical companies, research institutions, and governmental bodies have come to appreciate the importance of working together and consolidating their efforts. In May 2023, Pfizer (Vietnam) Limited Company and Vietnam Vaccine Joint Stock Company entered a memorandum of understanding (MoU) with the shared objective of comprehensive cooperation to safeguard public health, proactively combat diseases, and align with global advancements in healthcare, thereby positively impacting the well-being of the Vietnamese population. The primary focus of this joint project is to improve the proficiency of personnel in the development, implementation, and management of real-world data on vaccination, commonly known as "Real-World Evidence," in Vietnam. By doing so, the collaboration aims to gain valuable insights into vaccination patterns among the Vietnamese people, ensuring the safety and efficacy of vaccination practices.

#### Table of Contents:

- 1.□Research Methodology
- 2.□Project Scope & Definitions
- 3.□Executive Summary
- 4.□Vietnam Pneumococcal Vaccine Market Outlook, 2017-2031F
  - 4.1.□Market Size & Forecast
    - 4.1.1.□By Value
    - 4.1.2.□By Volume
  - 4.2.□By Type of Vaccine
    - 4.2.1.□Live Attenuated Vaccines
    - 4.2.2.□Inactivated Vaccines
    - 4.2.3.□Subunit Vaccines
      - 4.2.3.1.□Original Pathogen
      - 4.2.3.2.□Polysaccharide Vaccine
      - 4.2.3.3.□Conjugate Vaccine
      - 4.2.3.4.□Protein-based Vaccine
    - 4.2.4.□Recombinant Vaccine
  - 4.3.□By Vaccine Property
    - 4.3.1.□Adjuvanted
    - 4.3.2.□Non-adjuvanted
  - 4.4.□By Route of Administration
    - 4.4.1.□Intramuscular
    - 4.4.2.□Subcutaneous
    - 4.4.3.□Intradermal
    - 4.4.4.□Others
  - 4.5.□By Age group
    - 4.5.1.□Infants
    - 4.5.2.□Children

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 4.5.3.□Adults
- 4.6.□By End-user
- 4.6.1.□Hospitals
- 4.6.2.□Specialty Clinics
- 4.6.3.□Homecare
- 4.6.4.□Others
- 4.7.□By Distribution Channel
- 4.7.1.□Hospital
- 4.7.2.□Retail Pharmacy
- 4.7.3.□Online Pharmacy
- 4.7.4.□Non-Governmental Organizations
- 4.8.□By Region
- 4.8.1.□Northern
- 4.8.2.□Southern
- 4.8.3.□Central
- 4.9.□By Company Market Share (%), 2023
- 5.□Market Mapping, 2023
- 5.1.□By Type of Vaccine
- 5.2.□By Vaccine Property
- 5.3.□By Route of Administration
- 5.4.□By Age group
- 5.5.□By End-user
- 5.6.□By Distribution channel
- 5.7.□By Region
- 6.□Macro Environment and Industry Structure
- 6.1.□Supply Demand Analysis
- 6.2.□Import Export Analysis
- 6.3.□Value Chain Analysis
- 6.4.□PESTEL Analysis
- 6.4.1.□Political Factors
- 6.4.2.□Economic System
- 6.4.3.□Social Implications
- 6.4.4.□Technological Advancements
- 6.4.5.□Environmental Impacts
- 6.4.6.□Legal Compliances and Regulatory Policies (Statutory Bodies Included)
- 6.5.□Porter's Five Forces Analysis
- 6.5.1.□Supplier Power
- 6.5.2.□Buyer Power
- 6.5.3.□Substitution Threat
- 6.5.4.□Threat from New Entrant
- 6.5.5.□Competitive Rivalry
- 7.□Market Dynamics
- 7.1.□Growth Drivers
- 7.2.□Growth Inhibitors (Challenges and Restraints)
- 8.□Regulatory Framework and Innovation
- 8.1.□Clinical Trials
- 8.2.□Patent Landscape

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.3. Regulatory Approvals
- 8.4. Innovations/Emerging Technologies
- 9. Key Players Landscape
  - 9.1. Competition Matrix of Top Five Market Leaders
  - 9.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  - 9.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  - 9.4. SWOT Analysis (For Five Market Players)
  - 9.5. Patent Analysis (If Applicable)
- 10. Pricing Analysis
- 11. Case Studies
- 12. Key Players Outlook
  - 12.1. Pfizer Inc.
    - 12.1.1. Company Details
    - 12.1.2. Key Management Personnel
    - 12.1.3. Products & Services
    - 12.1.4. Financials (As reported)
    - 12.1.5. Key Market Focus & Geographical Presence
    - 12.1.6. Recent Developments
  - 12.2. Merck & Co., Inc.
  - 12.3. Walvax Biotechnology Co. Ltd.
  - 12.4. GlaxoSmithKline PLC.
  - 12.5. PnuVax Incorporated
  - 12.6. Novartis AG
  - 12.7. Serum Institute of Vietnam Pvt. Ltd.
  - 12.8. Panacea Biotec Limited
  - 12.9. Shenzhen Kangtai Biological Products Co., Ltd
  - 12.10. Sanofi Pasteur SA
- \*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work
- 13. Strategic Recommendations
- 14. About Us & Disclaimer

**Vietnam Pneumococcal Vaccine Market Assessment, By Type of Vaccine [Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Recombinant Vaccines], By Vaccine Property [Adjuvanted, Non-adjuvanted], By Route of Administration [Intramuscular, Subcutaneous, Intradermal, Others], By Age Group [Infants, Children, Adults], By End-user [Hospitals, Specialty Clinics, Homecare, Others], By Distribution Channel [Hospital, Retail Pharmacy, Online Pharmacy, Non-Governmental Organizations], By Region, By Opportunities and Forecast, 2017-2031F**

Market Report | 2024-04-19 | 129 pages | Market Xcel - Markets and Data

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$3300.00
	Muti-User/Corporate Licence	\$4500.00
	Custom Research License	\$7000.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-03"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)